01.07.2022 16:59

FMC Corp (FMC) Inks Deal to Acquire BioPhero for $200 Million

Folgen
Werbung
FMC Corporation FMC recently announced a definitive deal to acquire BioPhero ApS. The latter is a Denmark-based pheromone research and production company. The acquisition adds biologically produced state-of-the-art pheromone insect control technology to the company’s product portfolio and R&D pipeline, highlighting FMC's role as a leader in delivering innovative and sustainable crop protection solutions.BioPhero has established a highly efficient yeast fermentation process for producing pheromones at considerably lower costs and with fewer production steps than competitors' traditional chemical synthesis methods. The lower costs expand the pheromone addressable market from the current focus on specialty fruit and vegetables to now include the large row crop market.FMC projects pheromones and pheromone-based products to contribute roughly $1 billion in revenues at above company-average EBITDA margin by 2030. The acquisition is expected to complete at the end of the third quarter of 2022 and the purchase price of around $200 million will be paid at closing.FMC stated that this acquisition demonstrates its continuing commitment to investing in biologicals and adjacent technologies, expanding its world-class portfolio while advancing sustainable agriculture.Shares of FMC Corp have declined 1.4% in the past year compared with a 14.4% fall of the industry.Image Source: Zacks Investment ResearchFMC, in its last earnings call, stated that it continues to expect revenues between $5.25 billion and $5.55 billion for 2022, indicating a rise of 7% at the midpoint from 2021 levels. Sales are expected to be driven by higher volumes and prices in all regions.The company also forecasts adjusted EBITDA in the band of $1.32-$1.48 billion for 2022, indicating a 6% increase at the midpoint from 2021 levels.FMC now expects adjusted earnings per share for 2022 in the range of $6.70-$8.00 (compared with $6.8-$8.10 expected earlier), suggesting an increase of 6% at the midpoint from 2021 figures.Free cash flow for 2022 is projected to be $515-$735 million. The company also expects to repurchase $500-$600 million shares in 2022.For second-quarter 2022, revenues are projected in the band of $1.31-$1.39 billion, reflecting an increase of 9% at the midpoint compared with the prior-year quarter’s levels. Adjusted earnings are forecast in the range of $1.70-$2.00 per share, representing an increase of 2% at the midpoint from the prior-year quarter’s levels. It also expects adjusted EBITDA in the range of $330-$370 million for the quarter.FMC Corporation Price and Consensus  FMC Corporation price-consensus-chart | FMC Corporation Quote Zacks Rank & Key PicksFMC Corp currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the basic materials space are Allegheny Technologies Inc. ATI, Cabot Corporation CBT and Nutrien Ltd. NTR.Allegheny has a projected earnings growth rate of 1,076.9% for the current year. The Zacks Consensus Estimate for ATI's current-year earnings has been revised 40.4% upward in the past 60 days.Allegheny’s earnings beat the Zacks Consensus Estimate in the last four quarters. It has a trailing four-quarter earnings surprise of roughly 128.9%, on average. ATI has gained around 8.7% in a year and currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Cabot, currently sporting a Zacks Rank #1, has an expected earnings growth rate of 22.5% for the current year. The Zacks Consensus Estimate for CBT's earnings for the current year has been revised 6% upward in the past 60 days.Cabot’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average being 16.2%. CBT has gained around 10.2% over a year.Nutrien has a projected earnings growth rate of 174.6% for the current year. The Zacks Consensus Estimate for NTR’s current-year earnings has been revised 30.7% upward in the past 60 days.Nutrien’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, the average being 5.8%. NTR has gained 31% in a year. The company flaunts a Zacks Rank #1.Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Allegheny Technologies Incorporated (ATI): Free Stock Analysis Report FMC Corporation (FMC): Free Stock Analysis Report Cabot Corporation (CBT): Free Stock Analysis Report Nutrien Ltd. (NTR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Ausgewählte Hebelprodukte auf Acquire Ltd.
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Acquire Ltd.
Long
Short
Hebel wählen:
5x
10x
Name
Hebel
KO
Emittent
Quelle: Zacks

Nachrichten zu Fresenius Medical Care AG & Co. KGaA (FMC) St.

  • Relevant
    3
  • Alle
    7
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Fresenius Medical Care AG & Co. KGaA (FMC) St.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
08.08.2022Fresenius Medical Care BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.08.2022Fresenius Medical Care NeutralCredit Suisse Group
05.08.2022Fresenius Medical Care Equal WeightBarclays Capital
05.08.2022Fresenius Medical Care HoldWarburg Research
02.08.2022Fresenius Medical Care UnderweightJP Morgan Chase & Co.
08.08.2022Fresenius Medical Care BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
28.07.2022Fresenius Medical Care BuyJefferies & Company Inc.
27.07.2022Fresenius Medical Care BuyUBS AG
27.07.2022Fresenius Medical Care BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
25.07.2022Fresenius Medical Care BuyJefferies & Company Inc.
05.08.2022Fresenius Medical Care NeutralCredit Suisse Group
05.08.2022Fresenius Medical Care Equal WeightBarclays Capital
05.08.2022Fresenius Medical Care HoldWarburg Research
02.08.2022Fresenius Medical Care HoldDeutsche Bank AG
29.07.2022Fresenius Medical Care HoldDeutsche Bank AG
02.08.2022Fresenius Medical Care UnderweightJP Morgan Chase & Co.
29.07.2022Fresenius Medical Care UnderweightJP Morgan Chase & Co.
28.07.2022Fresenius Medical Care UnderweightJP Morgan Chase & Co.
21.07.2022Fresenius Medical Care UnderweightJP Morgan Chase & Co.
22.06.2022Fresenius Medical Care UnderweightJP Morgan Chase & Co.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Fresenius Medical Care AG & Co. KGaA (FMC) St. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Neue Funktionen als Erstes nutzen
Sie nutzen finanzen.net regelmäßig? Dann nutzen Sie jetzt neue Funktionen als Erstes!
Hier informieren!
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Nach Fed-Protokoll am Abend: Wall Street leichter -- DAX beendet Handel tiefrot -- Uniper erleidet deutlichen Verlust -- GM ruft Autos in den USA zurück -- HelloFresh, Siemens Energy, VW, BMW im Fokus

Rheinmetall und General Motors kooperieren bei LKW-Projekt der US Army. Amazon-Beschäftigte dringen auf weitere Gewerkschaft. Credit Suisse stuft Apple von 'Neutral' auf 'Outperform' hoch. Sanofi stellt klinisches Entwicklungsprogramm für das Brustkrebsmittel Amcenestrant ein. BVB denkt wegen der langen Winterpause über Auslandsreise nach - Diskussion um Ronaldo. Bei RTL-Deutschland muss Co-Chef Stephan Schäfer gehen.

Umfrage

Sollten die Corona-Regeln bei steigenden Infektionszahlen im Herbst wieder verschärft werden?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln